Is Vertex Stock Still a Good Buy?
Over the past ten years or so, Vertex Pharmaceuticals (NASDAQ:…
Sell
47
UG Quote, Financials, Valuation and Earnings
Last price:
$8.00
Seasonality move
:
5.21%
Day range:
$7.77 - $8.18
52-week range:
$7.73 - $16.25
Dividend yield:
8.87%
P/E ratio:
11.11x
P/S ratio:
2.98x
P/B ratio:
3.05x
Volume:
9.9K
Avg. volume:
12.6K
1-year change:
-5.73%
Market cap:
$36.2M
Revenue:
$12.2M
EPS (TTM):
$0.71
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, United-Guardian has -- downside to fair value with a price target of -- per share.
UG vs. S&P 500
-
Over the past 5 trading days, United-Guardian has underperformed the S&P 500 by -7.9% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
United-Guardian does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
United-Guardian revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter United-Guardian reported revenues of $2.5M.
Earnings Growth
-
United-Guardian earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter United-Guardian reported earnings per share of $0.11.
Enterprise value:
26.9M
EV / Invested capital:
--
Price / LTM sales:
2.98x
EV / EBIT:
7.36x
EV / Revenue:
2.20x
PEG ratio (5yr expected):
0.41x
EV / Free cash flow:
8.85x
Price / Operating cash flow:
11.95x
Enterprise value / EBITDA:
7.17x
Gross Profit (TTM):
$6.5M
Return On Assets:
24.31%
Net Income Margin (TTM):
26.69%
Return On Equity:
28.06%
Return On Invested Capital:
28.06%
Operating Margin:
22.46%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $12.7M | $10.9M | $12.2M | $2.6M | $2.5M | |
| Gross Profit | $6.7M | $5.4M | $6.5M | $1.4M | $1.3M | |
| Operating Income | $4M | $2.9M | $3.6M | $791.3K | $556.4K | |
| EBITDA | $4.2M | $3M | $3.7M | $822.6K | $582.7K | |
| Diluted EPS | $0.56 | $0.56 | $0.71 | $0.16 | $0.11 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $11.2M | $11.6M | $10M | $12.3M | $12.7M | |
| Total Assets | $11.9M | $12.2M | $10.6M | $12.9M | $13.8M | |
| Current Liabilities | $1.4M | $2.3M | $1.4M | $1.5M | $1.9M | |
| Total Liabilities | $1.6M | $2.4M | $1.4M | $1.5M | $1.9M | |
| Total Equity | $10.4M | $9.8M | $9.3M | $11.4M | $11.9M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $2.5M | $3.1M | $3.5M | $1.1M | $269.3K | |
| Cash From Investing | $897.6K | $4.7M | -$7.1M | -$580 | -$835.6K | |
| Cash From Financing | -- | -$459.4K | -$2.8M | -- | -- | |
| Free Cash Flow | $2.5M | $3M | $3M | $1M | -$45.9K | |
UG
Sector
Market Cap
$36.2M
$259.5M
Price % of 52-Week High
48.55%
73.98%
Dividend Yield
8.87%
0%
Shareholder Yield
--
3.16%
1-Year Price Total Return
-5.74%
-9.69%
Beta (5-Year)
0.845
0.419
Dividend yield:
8.87%
Annualized payout:
$0.60
Payout ratio:
84.79%
Growth streak:
1 years
Technicals
8-day SMA
Sell
Level
$8.33
200-day SMA
Sell
Level
$11.20
Bollinger Bands (100)
Sell
Level
8.91 - 10.71
Chaikin Money Flow
Sell
Level
-2.6M
20-day SMA
Sell
Level
$8.39
Relative Strength Index (RSI14)
Sell
Level
36.58
ADX Line
Sell
Level
15.59
Williams %R
Buy
Level
-86.7769
50-day SMA
Sell
Level
$9.31
MACD (12, 26)
Sell
Level
-0.32
25-day Aroon Oscillator
Sell
Level
-52
On Balance Volume
Neutral
Level
3.5M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (17.6145)
Buy
CA Score
(Annual)
Level (2.8265)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (9)
Buy
Ohlson Score
Level (-5.5774)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (6)
Sell
Fundamental Score
Level (6)
Revenue Forecast
Earnings per Share Forecast
Company Profile
United-Guardian Inc manufactures and markets cosmetic ingredients, pharmaceuticals, medical lubricants, and specialty industrial products. Its product portfolio includes Klensoft, Deselex, Renacidin, Lubrajel Fluid. The company's pharmaceutical products are sold to and distributed by full-line drug wholesalers throughout the United States. Its medical and specialty industrial products are sold directly by the company to the end-users of those products or, in some cases, to contract manufacturers used by some of those end users. It operates in one business segment and its current product lines are separated into four distinct product categories that are cosmetic ingredients, pharmaceuticals, medical lubricants and sexual wellness. It derives key revenue from the sales made in the U.S.
Stock Forecast FAQ
In the current month, UG has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The UG average analyst price target in the past 3 months is --.
-
Where Will United-Guardian Stock Be In 1 Year?
According to analysts, the consensus estimate is that United-Guardian share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About United-Guardian?
Analysts are divided on their view about United-Guardian share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that United-Guardian is a Sell and believe this share price will rise from its current level to --.
-
What Is United-Guardian's Price Target?
The price target for United-Guardian over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is UG A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for United-Guardian is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of UG?
You can purchase shares of United-Guardian via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase United-Guardian shares.
-
What Is The United-Guardian Share Price Today?
United-Guardian was last trading at $8.00 per share. This represents the most recent stock quote for United-Guardian. Yesterday, United-Guardian closed at $7.89 per share.
-
How To Buy United-Guardian Stock Online?
In order to purchase United-Guardian stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Okta Stock Finally Gaining Investor Confidence?
Given how digital transformation has proliferated, cyberattacks have also been…
Is The Trade Desk the Best Advertising Stock Now?
The worldly backdrop is now shrouded in heavy uncertainty and…
Stock Ideas
Buy
59
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
55
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 37x
Alerts
Buy
85
HIMS alert for Apr 30
Hims & Hers Health [HIMS] is down 5.48% over the past day.
Buy
54
EAT alert for Apr 30
Brinker International [EAT] is down 1.82% over the past day.
Sell
16
NSP alert for Apr 30
Insperity [NSP] is down 3.3% over the past day.
